HK Stock Connect Insight | IMPACT THERAP-B (07630.HK) Reports 316.8% H1 Revenue Growth, Down 34.32% Since Stock Connect Inclusion

NewTimeSpace News: On November 10, 2026, IMPACT THERAP-B closed at HKD 9.32, down 1.53% on the day, with turnover of HKD 39.0011 million.

According to public information, Impact Therapeutics listed on the Main Board of the Hong Kong Stock Exchange on May 13, 2026 at an offer price of HKD 20.10 per share, with a global offering of approximately 41.977 million H shares and net proceeds of approximately HKD 760 million. Its Hong Kong public offering was subscribed 2,282.4 times.

At present, since listing, the company's share price has ranged from a high of HKD 47.98 to a low of about HKD 7.74. As of November 10, 2026, the shares closed at HKD 9.32, about 53.63% below the offer price of HKD 20.10; since Stock Connect inclusion, the share price has fallen from HKD 14.19 at the close on September 7, 2026 to HKD 9.32, a decline of about 34.32%.

It is understood that Hang Seng Indexes Company announced on August 21, 2026 the results of its quarterly review of the Hang Seng Index series for the period ended June 30, 2026, under which Impact Therapeutics was included in the Hang Seng Composite Index, effective September 7, 2026. The Shanghai and Shenzhen stock exchanges subsequently adjusted their lists of eligible securities under Stock Connect, and the company's shares have been included in the list of eligible securities under Stock Connect since September 7, 2026.

Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on precision oncology therapies based on synthetic lethality, and is one of only three companies worldwide that possess both a commercial-stage PARP1/2 inhibitor and a clinical-stage next-generation selective PARP1 inhibitor.

On the financial front, the company's revenue for the first half of 2026 was RMB 105 million, up 316.8% year on year; R&D expenses were RMB 97.637 million, up 13.1% year on year; and loss for the period was RMB 90.81 million, narrowing 29.5% year on year.

Tianfeng Securities noted that senaparib has seen rapid volume growth following its inclusion in the National Reimbursement Drug List, with China sales up 877.8% year on year in the first half, covering all provinces in the Chinese mainland and nearly 1,200 medical institutions.